CO
COCH.US Envoy Medical Inc.
- Market cap
- USD 52.2M
- P/E
- -
- P/B
- 14.90x
- ROE
- -
- Dividend yield
- 3.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is COCH.US undervalued?
Graham numberThe Graham number of Envoy Medical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Envoy Medical Inc. fundamental analysis
No fundamental analysis for Envoy Medical Inc. yet.
Envoy Medical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Envoy Medical Inc.
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known…
Full company profileEnvoy Medical Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Envoy Medical Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 310K | 237K | 316K | 225K | 241K | 208K |
| Gross Profit | - | -459K | -261K | -473K | -517K | -633K | -905K |
| Operating Income | -701.00 | -6.87M | -8.71M | -18.4M | -19.3M | -22.3M | -22.8M |
| EBITDA | -701.00 | -8.60M | -15.8M | -29.8M | -19.8M | -21.9M | -17.6M |
| Net Income | -701.00 | -8.68M | -15.9M | -29.9M | -20.8M | -23.8M | -19.0M |
| EPS | 0.00 | -0.85 | -16 | -24 | -11 | -10 | -0.18 |
| Balance Sheet | |||||||
| Total Assets | 120K | 2.62M | 2.56M | 8.27M | 11.5M | 8.56M | 19.2M |
| Total Liabilities | 95.7K | 47.6M | 38.8M | 10.0M | 30.4M | 20.3M | 20.3M |
| Shareholders' Equity | 24.3K | -45.0M | -36.2M | -1.78M | -18.8M | -11.8M | -1.53M |
| Cash & Short-term Investments | 25.0K | 1.12M | 183K | 4.22M | 5.48M | 3.74M | 14.6M |
| Total Debt | - | 23.5M | 34.5M | 562K | 19.7M | 919K | 777K |
| Cash Flow | |||||||
| Operating Cash Flow | - | -6.94M | -8.81M | -17.1M | -17.9M | -18.2M | -22.1M |
| Capital Expenditure | - | 125K | 218K | 153K | 980K | 179K | 44.0K |
| Free Cash Flow | - | -7.06M | -9.02M | -17.2M | -18.9M | -18.4M | -22.1M |
| Ratios | |||||||
| ROE | -2.9% | - | - | - | - | - | - |
| ROA | -0.6% | -330.6% | -623.0% | -361.8% | -180.2% | -277.6% | -99.3% |
| Net Profit Margin | - | -2,798.4% | -6,718.6% | -9,469.0% | -9,242.2% | -9,857.3% | -9,144.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Envoy Medical Inc. dividends
- Dividend yield
- 3.49%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.82M | 0.78 | - |
| 2024 | USD 2.45M | 1.30 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Oct 26, 2026.
Who owns Envoy Medical Inc.
- Insiders 40.23%
- Institutions 23.29%
- Public & others 36.47%
- Shares outstanding 7.74M
- Free float 4.32M
Top funds holding COCH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 274K | 0.35% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 250K | 0.32% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 136K | 0.18% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 73.8K | 0.10% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 65.0K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 57.2K | 0.07% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 3.79K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding COCH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 15.3M | 19.77% | +100.00% | Jun 2026 |
| Bleichroeder LP | 6.25M | 8.08% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 880K | 1.14% | -0.17% | Jun 2026 |
| Geode Capital Management, LLC | 542K | 0.70% | +3.81% | Jun 2026 |
| The Colony Group LLC | 425K | 0.55% | +100.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 297K | 0.38% | +0.66% | Jun 2026 |
| UBS Group AG | 191K | 0.25% | +170.85% | Jun 2026 |
| Arcus Capital Partners LLC | 188K | 0.24% | 0.00% | Jun 2026 |
| ExodusPoint Capital Management, LP | 182K | 0.24% | 0.00% | Jun 2026 |
| Northern Trust Corp | 109K | 0.14% | -1.43% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 90.9K | 0.12% | +23.03% | Jun 2026 |
| CIBC Bancorp USA Inc. | 77.9K | 0.10% | 0.00% | Jun 2026 |
| LPL Financial Corp | 48.4K | 0.06% | +70.42% | Jun 2026 |
| Jane Street Group LLC | 31.2K | 0.04% | 0.00% | Jun 2026 |
| Meteora Capital, LLC | 28.1K | 0.04% | 0.00% | Jun 2026 |
| State Street Corp | 23.9K | 0.03% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 17.1K | 0.02% | 0.00% | Jun 2026 |
| AFG FIDUCIARY SERVICES LIMITED PARTNERSHIP | 12.0K | 0.02% | 0.00% | Jun 2026 |
| BlueStem Wealth Partners, LLC | 10.5K | 0.01% | 0.00% | Jun 2026 |
| Ballew Advisors, Inc | 10.1K | 0.01% | 0.00% | Jun 2026 |
Envoy Medical Inc. company profile
- Company name
- Envoy Medical Inc.
- Ticker
- COCH.US
- Exchange
- USA Stocks
- Listed since
- Apr 29, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 43
- Fiscal year end
- December
- Address
- 4875 White Bear Parkway, White Bear Lake, MN, United States, 55110
- Phone
- 877 900 3277
- Website
- envoymedical.com
About Envoy Medical Inc.
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Envoy Medical Inc. management
3- Mr. Brent T. Lucas Esq.CEO & Director · born 1982
- Mr. Robert M. PotashnickChief Accounting Officer, VP of Finance, Principal Financial Officer & Principal Accounting Officer · born 1981
- Ms. Karin SimonsonVP, General Counsel & Corporate Secretary